Supplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Observational analysis shows that CARM1i and PI3Ki synergistically inhibit growth in patient-derived xenograft organoids, indicating a potential therapeutic pathway.
Key Points
CARM1 inhibition significantly reduces the growth of patient-derived xenograft organoids, showcasing a promising therapeutic angle.
The combination of CARM1i and PI3Ki markedly enhances growth inhibition by targeting MAP2K4 in triple-negative breast cancer.
Assessment employing xenograft organoids indicates effective synergy of inhibitors, revealing a possible target for treatment.
These findings suggest a new avenue for therapeutic strategies in triple-negative breast cancer using targeted methylation.